Complete financial analysis of Theratechnologies Inc. (THTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Theratechnologies Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Helium One Global Ltd (HLOGF) Income Statement Analysis – Financial Results
- N1 Technologies Inc. (NTCHF) Income Statement Analysis – Financial Results
- Kopran Limited (KOPRAN.BO) Income Statement Analysis – Financial Results
- MTM Critical Metals Limited (MTM.AX) Income Statement Analysis – Financial Results
- Eureka Group Holdings Limited (EGH.AX) Income Statement Analysis – Financial Results
Theratechnologies Inc. (THTX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.theratech.com
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.76M | 80.06M | 69.82M | 66.05M | 63.22M | 44.05M | 33.23M | 27.60M | 22.55M | 5.90M | 7.13M | 13.66M |
| Cost of Revenue | 19.64M | 26.28M | 23.26M | 26.90M | 26.08M | 14.68M | 17.15M | 10.14M | 6.70M | 7.07M | 10.46M | 11.47M |
| Gross Profit | 62.13M | 53.78M | 46.56M | 39.15M | 37.14M | 29.38M | 16.07M | 17.47M | 15.85M | -1.17M | -3.33M | 2.18M |
| Gross Profit Ratio | 75.99% | 67.17% | 66.69% | 59.27% | 58.75% | 66.68% | 48.37% | 63.28% | 70.29% | -19.90% | -46.72% | 15.99% |
| Research & Development | 30.37M | 36.94M | 28.27M | 18.02M | 10.84M | 7.77M | 9.19M | 5.65M | 4.11M | 4.95M | 7.09M | 7.08M |
| General & Administrative | 15.62M | 17.36M | 14.62M | 12.23M | 8.33M | 5.83M | 4.51M | 3.57M | 2.99M | 4.00M | 3.55M | 5.50M |
| Selling & Marketing | 26.77M | 39.39M | 28.91M | 26.86M | 26.48M | 21.69M | 20.17M | 10.86M | 9.66M | 6.10M | 236.05K | 857.67K |
| SG&A | 42.39M | 56.75M | 43.53M | 39.09M | 34.81M | 25.02M | 24.67M | 14.54M | 12.74M | 10.10M | 3.84M | 6.36M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 850.00K | 22.07M |
| Operating Expenses | 72.76M | 93.69M | 71.80M | 57.11M | 45.65M | 32.79M | -30.64M | -16.76M | -14.28M | -8.21M | -901.69K | -16.97M |
| Cost & Expenses | 92.39M | 119.97M | 95.06M | 84.01M | 71.73M | 47.47M | -13.48M | -6.63M | -7.58M | -1.14M | 9.56M | -5.50M |
| Interest Income | 0.00 | 316.00K | 195.00K | 299.00K | 1.10M | 285.00K | 261.99K | 77.44K | 30.76K | 173.52K | 429.60K | 762.04K |
| Interest Expense | 10.55M | 6.50M | 5.66M | 5.36M | 4.99M | 2.53M | 1.07M | 1.44M | 1.87M | 1.05M | 12.25K | 23.12K |
| Depreciation & Amortization | 3.30M | 12.03M | 8.58M | 8.84M | 7.50M | 4.14M | 1.55M | 1.57M | 1.44M | 1.00M | 114.25K | 567.75K |
| EBITDA | -10.31M | -27.87M | -17.16M | -9.18M | 28.01K | 731.32K | -11.68M | 3.79M | 4.55M | -6.68M | -7.06M | -3.60M |
| EBITDA Ratio | -12.61% | -33.92% | -23.38% | -13.89% | 0.06% | 1.66% | -21.24% | 16.31% | 20.17% | -113.15% | -98.94% | -26.39% |
| Operating Income | -10.63M | -39.91M | -25.24M | -17.96M | -8.51M | -3.41M | -8.60M | 2.93M | 3.11M | -7.68M | -7.17M | -4.17M |
| Operating Income Ratio | -13.00% | -49.85% | -36.14% | -27.19% | -13.47% | -7.75% | -25.89% | 10.62% | 13.79% | -130.11% | -100.54% | -30.54% |
| Total Other Income/Expenses | -12.91M | -6.89M | -6.43M | -4.69M | -3.98M | -2.56M | -5.72M | -2.15M | -1.50M | -1.53M | 3.37M | -9.86M |
| Income Before Tax | -23.54M | -46.79M | -31.66M | -22.65M | -12.50M | -5.77M | -14.30M | 781.10K | 1.61M | -9.21M | -3.80M | -14.03M |
| Income Before Tax Ratio | -28.79% | -58.45% | -45.35% | -34.29% | -19.77% | -13.11% | -43.04% | 2.83% | 7.12% | -156.12% | -53.34% | -102.71% |
| Income Tax Expense | 421.00K | 443.00K | 63.00K | 16.00K | 4.99M | -1.25M | -2.17K | 475.81K | 426.91K | 27.17K | 24.55K | 5.03K |
| Net Income | -23.96M | -47.24M | -31.73M | -22.67M | -12.50M | -4.52M | -14.30M | 305.29K | 1.18M | -9.24M | -3.83M | -14.03M |
| Net Income Ratio | -29.30% | -59.00% | -45.44% | -34.32% | -19.77% | -10.27% | -43.04% | 1.11% | 5.23% | -156.58% | -53.69% | -102.75% |
| EPS | -0.91 | -1.98 | -1.37 | -1.18 | -0.65 | -0.24 | -0.78 | 0.02 | 0.06 | -0.61 | -0.25 | -0.93 |
| EPS Diluted | -0.91 | -1.98 | -1.37 | -1.18 | -0.65 | -0.24 | -0.78 | 0.02 | 0.07 | -0.61 | -0.25 | -0.92 |
| Weighted Avg Shares Out | 26.33M | 23.81M | 23.09M | 19.25M | 19.23M | 18.99M | 18.37M | 16.45M | 19.64M | 15.25M | 15.25M | 15.15M |
| Weighted Avg Shares Out (Dil) | 26.33M | 23.81M | 23.09M | 19.25M | 19.23M | 18.99M | 18.37M | 16.65M | 15.79M | 15.25M | 15.25M | 15.25M |
Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management
Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche
Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV
MONTREAL, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented data suggesting that tesamorelin may improve metabolic profiles in...
Theratechnologies Announces Path to Resume TH1902 Clinical Development
MONTREAL, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and optimize...
Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update
MONTREAL, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theratechnologies Inc. - THTX
New York, New York--(Newsfile Corp. - January 7, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. ("Theratechnologies" or the "Company") (NASDAQ: THTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or...
Open Letter to Shareholders from CEO Paul Levesque
Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan's Key Objectives Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan's Key Objectives
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Theratechnologies Inc. - THTX
New York, New York--(Newsfile Corp. - December 17, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. ("Theratechnologies" or the "Company") (NASDAQ: THTX). Such investors are advised to contact Robert S. Willoughby at [email protected] or...
Theratechnologies Announces Update from Ongoing TH1902 Study
This news release constitutes a “designated news release” for the purposes of the Company's prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. This news release constitutes a “designated news release” for...
Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays
MONTREAL, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies reports data from a tissue microarrays (TMAs) study demonstrating high expression...
Theratechnologies Inc. (THTX) Q3 2022 Earnings Call Transcript
Theratechnologies Inc. (NASDAQ:THTX ) Q3 2022 Earnings Conference Call October 13, 2022 8:30 AM ET Company Participants Elif McDonald - Head of Investor Relations Paul Levesque - President and Chief Executive Officer Philippe Dubuc - Chief Financial Officer Christian Marsolais...
Source: https://incomestatements.info
Category: Stock Reports